Skip to main content
AB Science logo

AB Science — Investor Relations & Filings

Ticker · AB ISIN · FR0010557264 LEI · 969500U43TVR8CCVBJ97 PA Manufacturing
Open in API
Filings indexed 742 across all filing types
Latest filing 2025-03-04 Regulatory Filings
Country FR France
Listing PA AB

About AB Science

https://www.ab-science.com

AB Science is a clinical-stage pharmaceutical company that researches, develops, and markets protein kinase inhibitors for human and veterinary medicine. The company focuses on developing innovative drugs for diseases with high unmet medical needs. Its pipeline is centered on two main compounds: masitinib and AB8939. Masitinib, a highly selective tyrosine kinase inhibitor, is under investigation for treating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's disease, as well as inflammatory diseases like mastocytosis. AB8939 is a microtubule destabilizer being developed for oncology, specifically for Acute Myeloid Leukemia (AML). The company also commercializes masitinib in veterinary medicine under the brand name Masivet®.

Recent filings

Filing Released Lang Actions
AB Science: Article from the leading publication Life Sciences Magazine featuring masitinib and its Phase 3 principal investigator, the neurologist Patrick Vermersch
Regulatory Filings Classification · 1% confidence The document is a press release from AB Science announcing that a leading publication, 'The Life Sciences Magazine,' featured an article about their compound Masitinib and its principal investigator, Professor Patrick Vermersch. This type of announcement, which publicizes external media coverage or research findings without being the primary financial report (like 10-K or IR) or a formal regulatory filing, typically falls under general corporate communications. Since it is not a specific announcement like a dividend (DIV), management change (MANG), or earnings release (ER), and it is not a report itself but an announcement *about* external coverage, the most appropriate category is Regulatory Filings (RNS) as a general corporate announcement or Regulatory Filings (RNS) as a fallback, or potentially Investor Presentation (IP) if it were structured as a presentation, but it reads like a news update. Given the options, and that it is a general corporate update/news item, RNS is the best fit as a general regulatory/corporate announcement category.
2025-03-04 English
AB Science today provides an update on its masitinib platform
Regulatory Filings Classification · 1% confidence The document is a press release from AB Science providing an update on their masitinib platform, including clinical trial progress, strategic outlook, and financial management (debt negotiation). It is not a formal financial report, audit, or proxy statement. While it mentions a webcast, it is primarily a corporate update on business operations and R&D, which fits best under the 'Regulatory Filings' (RNS) category as a general corporate announcement.
2025-01-29 English
AB Science fait aujourd'hui le point sur la plateforme masitinib
Investor Presentation Classification · 1% confidence The document is a press release from AB Science titled 'AB SCIENCE FAIT LE POINT SUR LA PLATEFORME MASITINIB'. It provides a detailed update on the company's clinical research programs (ALS, Multiple Sclerosis, Alzheimer's), market potential, and financial strategy (debt negotiation). While it mentions that a presentation is available on their website, the document itself contains the core strategic and clinical information rather than just being a notification of a report's availability. It functions as an investor-focused update on company strategy and R&D progress, which aligns best with the Investor Presentation (IP) category as it summarizes the key points of the presentation for the public.
2025-01-29 French
AB Science will host a live webcast on Tuesday January 28, 2025, from 5.30pm to 6.45pm CET
Report Publication Announcement Classification · 1% confidence The document is a press release announcing a live webcast scheduled for January 28, 2025, to provide an update on the company's masitinib platform. It includes the date, time, participants, and a link to access the event. This type of announcement, which schedules a call to discuss company updates (often related to results or strategy, though here it's platform update), is typically classified as a Call Transcript (CT) if the transcript were present, or an Earnings Release (ER) if it were results. Since this is an announcement *about* an upcoming event where discussion will occur, and it is not a formal regulatory filing like a 10-K or a standalone results announcement (ER), it most closely aligns with the context of a conference call event. However, given the options, an announcement of a specific event where management will speak, especially one that might cover operational or strategic updates, often precedes or is related to an Earnings Release or a general Investor Presentation. Since the document is short (3625 chars) and is purely an invitation/announcement for a future event, it doesn't fit perfectly into the defined categories for the *content* itself (like ER or IP). It is an announcement of a future event where a discussion will take place. If the content were the transcript, it would be CT. If it were the results, it would be ER. As a simple announcement of a scheduled event, it is closest to a general announcement. Given the options, and recognizing that many companies use press releases to announce investor/analyst calls, if this were an earnings call announcement, it would be related to ER. If it were a general strategy update call, it might lean towards IP. Since it's an announcement of a live event with Q&A potential, and not the final report or transcript, the best fit among the provided codes for an announcement of a management discussion event is often related to the context of the discussion. Since it's an update on the 'masitinib platform' (product development/pipeline), it's not a standard earnings call. Given the lack of a specific 'Webcast Announcement' code, and its nature as a brief announcement, it falls under the general regulatory/announcement category, RNS, or potentially related to Investor Presentation (IP) if the presentation material is the focus. However, the most common classification for announcements of management calls that aren't explicitly earnings is often RNS if no better fit exists. Let's re-evaluate: It is an announcement of a future event, not the content itself. This strongly suggests RPA or RNS based on the 'MENU VS MEAL' rule. Since it's not announcing the publication of a *report* but an *event*, RNS (General Regulatory Filings/Announcements) is the most appropriate fallback for a non-standard announcement.
2025-01-24 English
AB Science tiendra une conférence virtuelle le mardi 28 janvier 2025, de 17h30 à 18h45
Regulatory Filings Classification · 1% confidence The document is titled "COMMUNIQUE DE PRESSE" (Press Release) and explicitly announces a "CONFERENCE VIRTUELLE" (Virtual Conference) scheduled for a future date (January 28, 2025). It provides details about the participants (management and a medical expert) and includes a ZOOM link for access. This format—an announcement inviting participation in a discussion about the company's platform (masitinib)—is characteristic of a conference call or earnings call event, even if it's not explicitly labeled as an 'earnings' call. Since the text provided is the announcement/invitation for the event, and not the transcript itself, the most appropriate classification is Call Transcript (CT), as this category covers full text transcripts of company conference calls, and this announcement precedes or sets up such an event. Given the content is an invitation to a call where updates will be discussed, it strongly aligns with the context of a CT, although it is the pre-call announcement. However, looking closely at the definitions, 'CT' is for the *full text transcript*. This document is the *invitation* to the call. If the document were the transcript, it would be CT. Since it is the announcement of the call, it fits best under Regulatory Filings (RNS) as a general announcement, or potentially a proxy for an Investor Presentation (IP) if the call is strategic. Given the nature of the event (discussing the masitinib platform), it is a communication aimed at investors/analysts about operations, which often accompanies an ER or IR. Since it is purely an invitation to a future event, and not the transcript, the best fit among the provided options that covers general announcements not fitting elsewhere is RNS, or if we interpret the invitation as setting the stage for a future discussion, it's a type of investor communication. However, the content is purely logistical for a future call. If the call were about earnings, it would be related to ER. Since it's a general update call, and not the transcript itself, RNS (Regulatory Filings / miscellaneous announcement) is the safest classification for the invitation itself, unless we strictly interpret 'CT' as covering all related materials. Given the options, and the fact that it is an announcement about a future event, RNS is the most appropriate fallback for a non-standard announcement, though it is very close to the context of a CT. Re-evaluating: The document is a press release announcing a future conference call. This is a common precursor to an Earnings Release (ER) or a general update call. Since it is not the transcript (CT) nor the formal release (ER), and it is a specific announcement, RNS is the general catch-all. I will classify it as RNS as it is a press release announcing a future event, not the transcript itself.
2025-01-24 French
AB Science will participate in the Biomed Forum investors conference
Regulatory Filings Classification · 1% confidence The document is a short press release announcing that the management team of AB Science will participate in an upcoming investor conference (Biomed Forum). It contains company background, forward-looking statements, and contact information. It is not a full financial report (like 10-K or IR), an earnings release (ER), or a presentation (IP). Since it is an announcement related to investor relations activities and does not fit the specific categories like DIV, DIRS, or MANG, it falls best under the general 'Regulatory Filings' (RNS) category as a miscellaneous corporate communication, although 'Investor Presentation' (IP) might be considered if the announcement implied an attached presentation, which it does not. Given the nature of the announcement (participation in an investor event), RNS is the most appropriate fallback for a general corporate update that isn't a formal financial filing or specific event material.
2025-01-22 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.